Next Article in Journal
Intra-Articular Laser Treatment Plus Platelet Rich Plasma (PRP) Significantly Reduces Pain in Many Patients Who Had Failed Prior PRP Treatment
Previous Article in Journal
Mirtazapine for the Treatment of Chronic Pruritus
Article Menu

Export Article

Open AccessReview

Novel Delivery Systems for Checkpoint Inhibitors

1
School of Dental Medicine, Lake Erie College of Osteopathic Medicine, 4800 Lakewood Ranch Blvd, Bradenton, FL 34211, USA
2
School of Pharmacy, Lake Erie College of Osteopathic Medicine, 5000 Lakewood Ranch Blvd, Bradenton, FL 34211, USA
3
Department of Biostatistics, University of Florida, Gainesville, FL 32611, USA
4
Department of Internal Medicine, Southern Illinois University, Springfield, IL 62702, USA
5
Department of Radiation Oncology, University of Maryland School of Medicine, Baltimore, MD 21201, USA
*
Author to whom correspondence should be addressed.
Medicines 2019, 6(3), 74; https://doi.org/10.3390/medicines6030074
Received: 18 June 2019 / Revised: 8 July 2019 / Accepted: 10 July 2019 / Published: 11 July 2019
  |  
PDF [308 KB, uploaded 11 July 2019]

Abstract

Checkpoint inhibition (CPI) therapies have been proven to be powerful clinical tools in treating cancers. FDA approvals and ongoing clinical development of checkpoint inhibitors for treatment of various cancers highlight the immense potential of checkpoint inhibitors as anti-cancer therapeutics. The occurrence of immune-related adverse events, however, is a major hindrance to the efficacy and use of checkpoint inhibitors as systemic therapies in a wide range of patients. Hence, methods of sustained and tumor-targeted delivery of checkpoint inhibitors are likely to improve efficacy while also decreasing toxic side effects. In this review, we summarize the findings of the studies that evaluated methods of tumor-targeted delivery of checkpoint inhibitors, review their strengths and weaknesses, and discuss the outlook for therapeutic use of these delivery methods. View Full-Text
Keywords: immune-related adverse events; DNA-encoded monoclonal antibodies; platelets as delivery vehicles; resistance to checkpoint blockade; nanobodies; viral delivery of checkpoint inhibitors; hematopoietic stem cells; drug delivery systems; hydrogels; bacterial delivery immune-related adverse events; DNA-encoded monoclonal antibodies; platelets as delivery vehicles; resistance to checkpoint blockade; nanobodies; viral delivery of checkpoint inhibitors; hematopoietic stem cells; drug delivery systems; hydrogels; bacterial delivery
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).
SciFeed

Share & Cite This Article

MDPI and ACS Style

Lamichhane, P.; Deshmukh, R.; Brown, J.A.; Jakubski, S.; Parajuli, P.; Nolan, T.; Raja, D.; Badawy, M.; Yoon, T.; Zmiyiwsky, M.; Lamichhane, N. Novel Delivery Systems for Checkpoint Inhibitors. Medicines 2019, 6, 74.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Medicines EISSN 2305-6320 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top